Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

- PMLiVE

ICR calls for improved biomarker cancer tests to help personalise treatment

Each cancer has a unique pattern of biomarkers that can affect how effective treatments are

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

- PMLiVE

World Cancer Day: encouraging men to put their health first

A three-year campaign, running from 2022 to 2024, focuses on ‘Closing the Care Gap’

- PMLiVE

EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models

Endometrial cancer is the fourth most common cancer affecting women in the UK, with around 9,700 new cases every year

- PMLiVE

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines

Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients

- PMLiVE

Strategic behaviour

Strong strategising depends on your colleagues’ behaviour

- PMLiVE

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.

Avalere Health

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

- PMLiVE

AbbVie’s Rinvoq approved by MHRA for Crohn’s disease

Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms

A bundle of nerves

Medical experts have determined that we need to screen everyone for anxiety − and I mean everyone

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

- PMLiVE

Kite and Arcellx close multiple myeloma collaboration agreement

This haematological malignancy is the third most common  in Europe and the US and is incurable for most patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links